
Ben & Jerry’s Founders said at an interview this weekend that parent Unilever is in violation of the 2000 merger deal over its sale of Ben & Jerry’s business in Israel to a local licensee who could sell their products in the West Bank, reported Reuters.
“That agreement gave authority over the social mission to the independent board of Ben & Jerry’s. Unilever has usurped their authority and reversed the decision that was made and we can’t allow that to happen, we can’t sit idly by,” Ben Cohen said in a televised interview.
Partner Jerry Greenfield said the agreement is legally binding and needs to be adhered to. Unilever, in contrast, has said it retained the right to make operational decisions for Ben & Jerry’s, and that the sale could not be undone because it has irrevocably closed.
Ben & Jerry’s said earlier this month that it plans to amend its lawsuit challenging Unilever’s sale of the Israeli business in Federal court in Manhattan. Unilever must respond by Nov. 1.
In July 2021, the Burlington, Vermont based company decided to end sales in Israeli-occupied Palestinian territories, calling it “inconsistent” with the progressive values and social mission it retained the right to promote.
That decision prompted a backlash against Unilever, including divestments by pension funds from the consumer goods company and accusations of anti-Semitism by some Jewish groups.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas